Vera Therapeutics director receives stock option grant

Vera Therapeutics director Kimball Hall received a grant of stock options covering 17,084 shares of Class A common stock at an exercise price of $34.35 per share.

Rhea-AI Filing Summary

Vera Therapeutics director Kimball Hall received a grant of stock options covering 17,084 shares of Class A common stock at an exercise price of $34.35 per share. These options expire on May 20, 2036 and are held directly.

The options will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, provided Hall remains in continuous service. They will also vest in full upon a change in control, again contingent on continuous service through that date.

Insider Trade Summary

Grant/Award: 17,084 shares

Grant/Award 1 txn

Insider Hall Kimball

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	17,084	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 17,084 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

Key Figures

Option grant size: 17,084 options Exercise price: $34.35 per share Underlying shares: 17,084 shares +2 more

5 metrics

Option grant size 17,084 options Stock Option (right to buy) granted to director Kimball Hall

Exercise price $34.35 per share Conversion or exercise price for underlying Class A common stock

Underlying shares 17,084 shares Class A Common Stock underlying the stock option grant

Expiration date May 20, 2036 Option expiration date for the granted stock options

Options held after grant 17,084 options Total derivative securities following the reported transaction

Key Terms

Stock Option (right to buy), Class A Common Stock, change in control, continuous service, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Class A Common Stock financial

"underlying_security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

change in control financial

"the shares will vest in full upon a change in control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

annual stockholder meeting financial

"the date of the Company's 2027 annual stockholder meeting"

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vera Therapeutics (VERA) report in this Form 4?

Vera Therapeutics reported a stock option grant to director Kimball Hall for 17,084 shares of Class A common stock. The options are compensation-related, not an open-market purchase or sale, and give the right to buy shares at a fixed price if they vest.

How many Vera Therapeutics (VERA) options did Kimball Hall receive and at what price?

Kimball Hall received stock options for 17,084 underlying shares at an exercise price of $34.35 per share. This grant gives the director the potential to buy those shares at that fixed price if the vesting conditions are met before the options expire.

When do Kimball Hall’s Vera Therapeutics (VERA) stock options vest?

The stock options vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting. Vesting requires Hall’s continuous service through that date, aligning the grant with ongoing board service and company governance milestones.

What happens to Kimball Hall’s Vera Therapeutics (VERA) options if there is a change in control?

All 17,084 options vest in full upon a change in control, provided Hall remains in continuous service through the change-in-control date. This accelerates vesting, ensuring the director’s compensation recognizes a significant corporate event such as a merger or acquisition impacting Vera Therapeutics.

When do Kimball Hall’s Vera Therapeutics (VERA) stock options expire?

The granted stock options expire on May 20, 2036, setting a long-term window to exercise once vested. After that expiration date, any unexercised options become worthless, so value realization depends on vesting, continuous service, and future share price relative to the $34.35 exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/26/2026 - 04:18 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hall Kimball

(Last) (First) (Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$34.35	05/21/2026		A		17,084		(1)	05/20/2036	Class A Common Stock	17,084	$0	17,084	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

	/s/ Joseph R. Young, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)